专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004110490A2 METHOD OF TUMOR REGRESSION WITH VEGF INHIBITORS 审中-公开
标题翻译： VEGF抑制剂的肿瘤反应方法
公开(公告)号：WO2004110490A2
公开(公告)日：2004-12-23
申请号：PCT/US2004017721
申请日：2004-06-04
申请人： REGENERON PHARMA , UNIV COLUMBIA , KANDEL JESSICA , HOLASH JOCELYN , YAMASHIRO DARRELL , HUANG JIANZHONG , YANCOPOULOS GEORGE , RUDGE JOHN
发明人： KANDEL JESSICA , HOLASH JOCELYN , YAMASHIRO DARRELL , HUANG JIANZHONG , YANCOPOULOS GEORGE , RUDGE JOHN
IPC分类号： A61K38/18 , A61P35/00 , A61K45/00
CPC分类号： A61K38/179 , A61K2039/505 , C07K2319/30
摘要： Methods of regressing or inhibiting a tumor in a subject by administering an agent capable of blocking, inhibiting, or ameliorating vascular endothelial growth factor (VEGF)-mediated activity to a subject in need thereof such that the tumor is regressed or inhibited. The method of the invention results in a reduction of tumor size and inhibition of tumor metastases. This method is particularly useful for patients suffering from bulky, metastatic cancers.
摘要翻译：通过施用能够阻断，抑制或改善对有需要的受试者的血管内皮生长因子（VEGF）介导的活性的试剂使得肿瘤被退化或抑制，从而在受试者中回归或抑制肿瘤的方法。本发明的方法导致肿瘤大小的减小和肿瘤转移的抑制。该方法对于患有体积大，转移性癌症的患者特别有用。

2. 发明专利

SG10202102617QA ANTI-STEAP2 ANTIBODIES, ANTIBODY-DRUG CONJUGATES, AND BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND STEAP2 AND CD3, AND USES THEREOF 未知
公开(公告)号：SG10202102617QA
公开(公告)日：2021-04-29
申请号：SG10202102617Q
申请日：2017-09-22
申请人： REGENERON PHARMA
发明人： RUDGE JOHN , DELFINO FRANK , HABER LAURIC , SMITH ERIC , KIRSHNER JESSICA R , CRAWFORD ALISON , NITTOLI THOMAS
摘要： The protein known as six-transmembrane epithelial antigen of prostate 2 (STEAP2) is highly expressed in prostate cancer and is associated with the expression of other prostate cancer-associated genes. The present invention provides novel full-length human IgG antibodies that bind to human STEAP2 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both STEAP2 and CD3 and activate T cells via the CD3 complex in the presence of STEAP2-expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds humanSTEAP2. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing STEAP2. The bispecific antigen-binding molecules of the invention are useful for the treatment of prostate diseases and disorders in which an upregulated or induced STEAP2-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of prostate cancers, including castrate-resistant prostate cancer. The present invention also includes anti-STEAP2 antibody drug conjugates which inhibit tumor growth in vivo.

3. 发明专利

CL2019000738A1 Anticuerpos anti-steap2, conjugados anticuerpo-fármaco, y moléculas de fijación al antígeno biespecíficas que se fijan a steap2 y cd3, y usos de estos. 未知
公开(公告)号：CL2019000738A1
公开(公告)日：2019-05-31
申请号：CL2019000738
申请日：2019-03-21
申请人： REGENERON PHARMA
发明人： NITTOLI THOMAS , DELFINO FRANK , HABER LAURIC , SMITH ERIC , CRAWFORD ALISON , RUDGE JOHN , KIRSHNER JESSICA R
IPC分类号： A61P35/00 , A61K47/68 , C07K16/28 , C07K16/30
摘要： LA PROTEÍNA CONOCIDA COMO ANTÍGENO EPITELIAL DE SEIS TRANSMEMBRANAS DE PRÓSTATA 2 (STEAP2) SE EXPRESA ALTAMENTE EN EL CÁNCER DE PRÓSTATA Y ESTÁ ASOCIADA CON LA EXPRESIÓN DE OTROS GENES ASOCIADOS CON EL CÁNCER DE PRÓSTATA. LA PRESENTE INVENCIÓN PROPORCIONA ANTICUERPOS CONTRA IGG HUMANA DE LONGITUD COMPLETA NOVEDOSOS QUE SE FIJAN A STEAP2 HUMANO (ANTICUERPOS MONOESPECÍFICOS). LA PRESENTE INVENCIÓN TAMBIÉN PROPORCIONA ANTICUERPOS BIESPECÍFICOS (BSABS) NOVEDOSOS QUE SE FIJAN A STEAP2 Y CD3 Y ACTIVAN LOS LINFOCITOS T A TRAVÉS DEL COMPLEJO CD3 EN PRESENCIA DE TUMORES QUE EXPRESAN STEAP2. DE ACUERDO CON DETERMINADAS FORMAS DE REALIZACIÓN, LA PRESENTE INVENCIÓN PROPORCIONA MOLÉCULAS DE FIJACIÓN AL ANTÍGENO BIESPECÍFICAS QUE COMPRENDEN UN PRIMER DOMINIO DE FIJACIÓN AL ANTÍGENO QUE SE FIJA ESPECÍFICAMENTE A CD3 HUMANO Y DE MONO, Y UNA SEGUNDA MOLÉCULA DE FIJACIÓN AL ANTÍGENO QUE SE FIJA ESPECÍFICAMENTE A STEAP2 HUMANO. EN DETERMINADAS FORMAS DE REALIZACIÓN, LAS MOLÉCULAS DE FIJACIÓN AL ANTÍGENO BIESPECÍFICAS DE LA PRESENTE INVENCIÓN PUEDEN INHIBIR EL CRECIMIENTO DE TUMORES QUE EXPRESAN STEAP2. LAS MOLÉCULAS DE FIJACIÓN AL ANTÍGENO BIESPECÍFICAS DE LA INVENCIÓN SON ÚTILES PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS DE LA PRÓSTATA EN LOS QUE SE DESEA Y/O ES BENEFICIOSA UNA RESPUESTA INMUNITARIA DIRIGIDA A STEAP2 INDUCIDA O REGULADA DE MANERA ASCENDENTE. POR EJEMPLO, LOS ANTICUERPOS BIESPECÍFICOS DE LA INVENCIÓN SON ÚTILES PARA EL TRATAMIENTO DE TIPOS DE CÁNCER DE PRÓSTATA, QUE INCLUYEN EL CÁNCER DE PRÓSTATA RESISTENTE A LA CASTRACIÓN. LA PRESENTE INVENCIÓN TAMBIÉN INCLUYE CONJUGADOS ANTICUERPO-FÁRMACO ANTI-STEAP2 QUE INHIBEN EL CRECIMIENTO DE TUMORES IN VIVO.

4. 发明专利

PH12019500603A1 ANTI-STEAP2 ANTIBODIES, ANTIBODY-DRUG CONJUGATES, AND BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND STEAP2 AND CD3, AND USES THEREOF 未知
公开(公告)号：PH12019500603A1
公开(公告)日：2019-06-03
申请号：PH12019500603
申请日：2019-03-19
申请人： REGENERON PHARMA
发明人： RUDGE JOHN , DELFINO FRANK , HABER LAURIC , SMITH ERIC , KIRSHNER JESSICA R , CRAWFORD ALISON , NITTOLI THOMAS
IPC分类号： A61K47/68 , A61P35/00 , C07K16/28 , C07K16/30
摘要： The protein known as six-transmembrane epithelial antigen of prostate 2 (STEAP2) is highly expressed in prostate cancer and is associated with the expression of other prostate cancer-associated genes. The present invention provides novel full-length human IgG antibodies that bind to human STEAP2 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both STEAP2 and CD3 and activate T cells via the CD3 complex in the presence of STEAP2 -expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds humanSTEAP2. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing STEAP2. The bispecific antigen-binding molecules of the invention are useful for the treatment of prostate diseases and disorders in which an upregulated or induced STEAP2 -targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of prostate cancers, including castrate-resistant prostate cancer. The present invention also includes anti-STEAP2 antibody drug conjugates which inhibit tumor growth in vivo.

5. 发明专利

CA2519875A1 USE OF VEGF INHIBITORS FOR TUMOR REGRESSION 未知
公开(公告)号：CA2519875A1
公开(公告)日：2004-12-23
申请号：CA2519875
申请日：2004-06-04
申请人： REGENERON PHARMA , UNIV COLUMBIA
发明人： YAMASHIRO DARRELL , HOLASH JOCELYN , KANDEL JESSICA , HUANG JIANZHONG , RUDGE JOHN , YANCOPOULOS GEORGE
IPC分类号： A61K48/00 , A61K31/7088 , A61K38/18 , A61K39/395 , A61K45/00 , A61P35/00
摘要： Methods of regressing or inhibiting a tumor in a subject by administering an agent capable of blocking, inhibiting, or ameliorating vascular endothelial growth factor (VEGF)-mediated activity to a subject in need thereof such tha t the tumor is regressed or inhibited. The method of the invention results in a reduction of tumor size and inhibition of tumor metastases. This method is particularly useful for patients suffering from bulky, metastatic cancers.

6. 发明专利

AU2017331361A1 Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof 未知
公开(公告)号：AU2017331361A1
公开(公告)日：2019-04-11
申请号：AU2017331361
申请日：2017-09-22
申请人： REGENERON PHARMA
发明人： RUDGE JOHN , DELFINO FRANK , HABER LAURIC , SMITH ERIC , KIRSHNER JESSICA R , CRAWFORD ALISON , NITTOLI THOMAS
IPC分类号： C07K16/30 , A61K47/68 , A61P35/00 , C07K16/28
摘要： The protein known as six-transmembrane epithelial antigen of prostate 2 (STEAP2) is highly expressed in prostate cancer and is associated with the expression of other prostate cancer-associated genes. The present invention provides novel full-length human IgG antibodies that bind to human STEAP2 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both STEAP2 and CD3 and activate T cells via the CD3 complex in the presence of STEAP2 -expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds humanSTEAP2. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing STEAP2. The bispecific antigen-binding molecules of the invention are useful for the treatment of prostate diseases and disorders in which an upregulated or induced STEAP2 -targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of prostate cancers, including castrate-resistant prostate cancer. The present invention also includes anti-STEAP2 antibody drug conjugates which inhibit tumor growth in vivo.

7. 发明专利

CA2598452A1 TREATING ANEMIA BY INHIBITION OF VEGF 未知
公开(公告)号：CA2598452A1
公开(公告)日：2006-09-21
申请号：CA2598452
申请日：2006-03-10
申请人： REGENERON PHARMA
发明人： RUDGE JOHN , YANCOPOULOS GEORGE D , STAHL NEIL , HOLASH JOCELYN , CEDARBAUM JESSE M
IPC分类号： A61K38/17 , A61P7/06

8. 发明专利

AU2006223314A1 Treating anemia by inhibition of VEGF 未知
公开(公告)号：AU2006223314A1
公开(公告)日：2006-09-21
申请号：AU2006223314
申请日：2006-03-10
申请人： REGENERON PHARMA
发明人： CEDARBAUM JESSE M , RUDGE JOHN , STAHL NEIL , HOLASH JOCELYN , YANCOPOULOS GEORGE D
IPC分类号： A61K38/17 , A61P7/06

9. 发明专利

AU2004247095A1 Use of VEGF inhibitors for tumor regression 未知
公开(公告)号：AU2004247095A1
公开(公告)日：2004-12-23
申请号：AU2004247095
申请日：2004-06-04
申请人： REGENERON PHARMA , UNIV COLUMBIA
发明人： RUDGE JOHN , KANDEL JESSICA , HOLASH JOCELYN , YAMASHIRO DARRELL , HUANG JIANZHONG , YANCOPOULOS GEORGE
IPC分类号： A61K38/18 , A61P35/00 , A61K45/00
摘要： Methods of regressing or inhibiting a tumor in a subject by administering an agent capable of blocking, inhibiting, or ameliorating vascular endothelial growth factor (VEGF)-mediated activity to a subject in need thereof such that the tumor is regressed or inhibited. The method of the invention results in a reduction of tumor size and inhibition of tumor metastases. This method is particularly useful for patients suffering from bulky, metastatic cancers.

10. 发明专利

CO2019003923A2 Anticuerpos anti-steap2, conjugados anticuerpo-fármaco, y moléculas de fijación al antígeno biespecíficas que se fijan a steap2 y cd3, y usos de estos 未知
公开(公告)号：CO2019003923A2
公开(公告)日：2019-04-30
申请号：CO2019003923
申请日：2019-04-17
申请人： REGENERON PHARMA
发明人： KIRSHNER JESSICA R , DELFINO FRANK , NITTOLI THOMAS , RUDGE JOHN , HABER LAURIC , SMITH ERIC , CRAWFORD ALISON
IPC分类号： C07K16/30 , A61P35/00 , C07K16/28
摘要： RESUMEN La proteína conocida como antígeno epitelial de seis transmembranas de próstata 2 (STEAP2) se expresa altamente en el cáncer de próstata y está asociada con la expresión de otros genes asociados con el cáncer de próstata. La presente invención proporciona anticuerpos contra IgG humana de longitud completa novedosos que se fijan a STEAP2 humano (anticuerpos monoespecíficos). La presente invención también proporciona anticuerpos biespecíficos (bsAbs) novedosos que se fijan a STEAP2 y CD3 y activan los linfocitos T a través del complejo CD3 en presencia de tumores que expresan STEAP2. De acuerdo con determinadas formas de realización, la presente invención proporciona moléculas de fijación al antígeno biespecíficas que comprenden un primer dominio de fijación al antígeno que se fija específicamente a CD3 humano y de mono, y una segunda molécula de fijación al antígeno que se fija específicamente a STEAP2 humano. En determinadas formas de realización, las moléculas de fijación al antígeno biespecíficas de la presente invención pueden inhibir el crecimiento de tumores que expresan STEAP2. Las moléculas de fijación al antígeno biespecíficas de la invención son útiles para el tratamiento de enfermedades y trastornos de la próstata en los que se desea y/o es beneficiosa una respuesta inmunitaria dirigida a STEAP2 inducida o regulada de manera ascendente. Por ejemplo, los anticuerpos biespecíficos de la invención son útiles para el tratamiento de tipos de cáncer de próstata, que incluyen el cáncer de próstata resistente a la castración. La presente invención también incluye conjugados anticuerpo-fármaco anti-STEAP2 que inhiben el crecimiento de tumores in vivo.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式